Takuji Okusaka

Papers

1

Total Citations

35

H-Index

1

About

Dr. Takuji Okusaka is a leading authority in hepatobiliary and pancreatic oncology, with a research focus deeply rooted in improving therapeutic outcomes for patients with pancreatic cancer. His major contributions center on the clinical application and optimization of gemcitabine-based chemotherapy, a cornerstone treatment for advanced pancreatic cancer. Notably, his 2010 work on survival prediction for patients receiving gemcitabine sought to address the critical challenge of variable patient responses. By employing liquid chromatography-mass spectrometry (LC-MS) to identify novel biomarkers, Okusaka’s research aims to move beyond a one-size-fits-all approach, striving to personalize treatment and identify which patients are most likely to benefit. This work, cited 35 times, underscores his commitment to precision medicine in a notoriously difficult-to-treat malignancy. Through his investigations into predictive biomarkers and clinical outcomes, Dr. Okusaka has significantly advanced the understanding of pancreatic cancer management, providing a foundation for more tailored and effective therapeutic strategies that directly impact patient survival and quality of care.

Research Focus

Key Achievements

1
H-Index
1
Papers
35
Total Citations
35
Avg Citations/Paper
🏆 Most Cited Paper
Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment
35 citations · 2010
📈 Most Prolific Year: 2010 (1 Papers)
🤝 Key Collaborators: 17

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago